JP2018527397A - 徐放性オランザピン製剤 - Google Patents

徐放性オランザピン製剤 Download PDF

Info

Publication number
JP2018527397A
JP2018527397A JP2018515050A JP2018515050A JP2018527397A JP 2018527397 A JP2018527397 A JP 2018527397A JP 2018515050 A JP2018515050 A JP 2018515050A JP 2018515050 A JP2018515050 A JP 2018515050A JP 2018527397 A JP2018527397 A JP 2018527397A
Authority
JP
Japan
Prior art keywords
olanzapine
patient
dosage form
poly
pharmaceutical dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527397A5 (cg-RX-API-DMAC7.html
Inventor
マーク・アラン・スミス
カリーネ・クラーセン−プント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of JP2018527397A publication Critical patent/JP2018527397A/ja
Publication of JP2018527397A5 publication Critical patent/JP2018527397A5/ja
Priority to JP2021110240A priority Critical patent/JP2021167331A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)
JP2018515050A 2015-09-21 2016-09-21 徐放性オランザピン製剤 Pending JP2018527397A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021110240A JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
US62/221,290 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110240A Division JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Publications (2)

Publication Number Publication Date
JP2018527397A true JP2018527397A (ja) 2018-09-20
JP2018527397A5 JP2018527397A5 (cg-RX-API-DMAC7.html) 2019-10-31

Family

ID=57047342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515050A Pending JP2018527397A (ja) 2015-09-21 2016-09-21 徐放性オランザピン製剤
JP2021110240A Pending JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021110240A Pending JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Country Status (21)

Country Link
US (4) US20170079985A1 (cg-RX-API-DMAC7.html)
EP (2) EP4331570A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018527397A (cg-RX-API-DMAC7.html)
KR (1) KR20180054627A (cg-RX-API-DMAC7.html)
CN (2) CN116942677A (cg-RX-API-DMAC7.html)
AR (1) AR106085A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016328958B2 (cg-RX-API-DMAC7.html)
CA (1) CA2998504C (cg-RX-API-DMAC7.html)
CL (1) CL2018000727A1 (cg-RX-API-DMAC7.html)
DK (1) DK3352735T3 (cg-RX-API-DMAC7.html)
EA (1) EA201890788A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960753T3 (cg-RX-API-DMAC7.html)
FI (1) FI3352735T3 (cg-RX-API-DMAC7.html)
HU (1) HUE063850T2 (cg-RX-API-DMAC7.html)
IL (3) IL295161A (cg-RX-API-DMAC7.html)
MX (2) MX2018003380A (cg-RX-API-DMAC7.html)
NZ (1) NZ740665A (cg-RX-API-DMAC7.html)
PL (1) PL3352735T3 (cg-RX-API-DMAC7.html)
PT (1) PT3352735T (cg-RX-API-DMAC7.html)
TW (1) TWI798161B (cg-RX-API-DMAC7.html)
WO (1) WO2017053346A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511483A (ja) * 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
JP2023505963A (ja) * 2019-12-20 2023-02-14 ▲ユ▼展新藥生技股分有限公司 ケタミンパモエート塩の長時間作用型注射用製剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836615A (zh) * 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007269778A (ja) * 2006-02-17 2007-10-18 Pfizer Inc 黄斑変性症及び関連眼状態の治療方法
JP2008538751A (ja) * 2005-04-13 2008-11-06 ファイザー・プロダクツ・インク ナノ粒子組成物を持続放出するための注射用デポ製剤および方法
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EA002825B1 (ru) * 1997-09-30 2002-10-31 Эли Лилли Энд Компани Препарат 2-метилтиенобензодиазепина
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
ATE552032T1 (de) * 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
EP2309982A2 (en) 2008-06-03 2011-04-20 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
US9561352B2 (en) 2009-03-12 2017-02-07 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
LT2394663T (lt) * 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
CN103491946B (zh) 2010-12-29 2016-08-10 美蒂森 可生物降解的药物释放组合物
SI2717914T1 (sl) 2011-06-10 2020-07-31 Ramscor Inc. Formulacije z zadržanim sproščanjem za dostavo proteinov v oko in postopki njihove priprave
MX350469B (es) 2011-10-24 2017-09-07 Endo Pharmaceuticals Solutions Composiciones para el suministro de farmacos implantables y metodos para su tratamiento.
MX364864B (es) 2012-01-23 2019-05-09 Allergan Inc Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
WO2014202214A1 (en) 2013-06-20 2014-12-24 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538751A (ja) * 2005-04-13 2008-11-06 ファイザー・プロダクツ・インク ナノ粒子組成物を持続放出するための注射用デポ製剤および方法
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
JP2007269778A (ja) * 2006-02-17 2007-10-18 Pfizer Inc 黄斑変性症及び関連眼状態の治療方法
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511483A (ja) * 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
US11813359B2 (en) 2017-03-20 2023-11-14 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
JP2023505963A (ja) * 2019-12-20 2023-02-14 ▲ユ▼展新藥生技股分有限公司 ケタミンパモエート塩の長時間作用型注射用製剤
JP7764373B2 (ja) 2019-12-20 2025-11-05 ▲ユ▼展新藥生技股分有限公司 ケタミンパモエート塩の長時間作用型注射用製剤

Also Published As

Publication number Publication date
AU2016328958A1 (en) 2018-04-05
US20180264001A1 (en) 2018-09-20
US20240238307A1 (en) 2024-07-18
HUE063850T2 (hu) 2024-02-28
MX2018003380A (es) 2018-08-16
AU2016328958B2 (en) 2022-04-21
DK3352735T3 (da) 2023-10-30
IL258086A (en) 2018-05-31
FI3352735T3 (fi) 2023-10-20
AU2022206695A1 (en) 2022-08-11
PT3352735T (pt) 2023-10-30
US20220323458A1 (en) 2022-10-13
EP4331570A1 (en) 2024-03-06
US20170079985A1 (en) 2017-03-23
KR20180054627A (ko) 2018-05-24
AR106085A1 (es) 2017-12-13
WO2017053346A1 (en) 2017-03-30
JP2021167331A (ja) 2021-10-21
IL295161A (en) 2022-09-01
TW201726144A (zh) 2017-08-01
TWI798161B (zh) 2023-04-11
CA2998504A1 (en) 2017-03-30
EA201890788A1 (ru) 2018-09-28
PL3352735T3 (pl) 2024-01-29
CA2998504C (en) 2023-06-20
EP3352735A1 (en) 2018-08-01
MX2022007315A (es) 2022-07-13
HK1255946A1 (en) 2019-09-06
CN116942677A (zh) 2023-10-27
CN108289834A (zh) 2018-07-17
IL275735A (en) 2020-08-31
NZ740665A (en) 2023-04-28
EP3352735B1 (en) 2023-08-30
CL2018000727A1 (es) 2018-09-28
ES2960753T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
US20240238307A1 (en) Sustained release olanzapine formulations
US20250073166A1 (en) Sustained Release Olanzapine Formulations
JP6894436B2 (ja) 徐放性シクロスポリン添加微粒子
US12036323B2 (en) Biodegradable polymer microsphere compositions for parenteral administration
KR20170134583A (ko) 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
WO2017096530A1 (zh) 癸氧喹酯固体分散体、其制备方法和用途
CN114748428A (zh) 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
HK40106695A (en) Sustained release olanzapine formulations
HK1255946B (en) Sustained release olanzapine formulations
Jin et al. Preparation and characterization of morphine gelatine microspheres

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210701

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210719

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210719

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221011

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221024

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20221024

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230123

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20230201